{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:41:02Z","timestamp":1792172462676,"version":"4.4.0"},"reference-count":108,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Chimeric antigen receptor (CAR) T-cell therapy has emerged as a groundbreaking immunotherapeutic approach, particularly for oncohematological patients who are refractory to conventional treatments. As clinical trials expand the applications of CAR T-cell therapy beyond hematologic malignancies, a critical understanding of its associated toxicities, particularly cardiovascular complications, becomes imperative. This review synthesizes current literature on the interplay between cytokine release syndrome (CRS) and cardiotoxicity related to CAR T-cell therapy, emphasizing the potential severity of these adverse events. While significant progress has been made in managing CRS, the cardiac manifestations\u2014ranging from mild events to life-threatening complications\u2014remain underreported in pivotal studies. We explore the incidence and nature of cardiotoxicity in real-world and clinical trial settings, identify risk factors contributing to cardiovascular events, and propose guidelines for pre-therapy evaluations, post-infusion monitoring, and management strategies. By highlighting the urgent need for heightened awareness and proactive care, this review aims to enhance patient safety and optimize outcomes in the evolving landscape of CAR T-cell therapy.<\/jats:p>","DOI":"10.3389\/fphar.2025.1578157","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:13:26Z","timestamp":1746663206000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Cardiovascular toxicities associated with chimeric antigen receptor T-cell therapy"],"prefix":"10.3389","volume":"16","author":[{"given":"Jia-Hui","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun-Yao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yichuan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.3389\/fphys.2018.01866","article-title":"Cardiolipotoxicity, inflammation, and arrhythmias: role for interleukin-6 molecular mechanisms","volume":"9","author":"Al\u00ed","year":"2018","journal-title":"Front. Physiol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","article-title":"T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma","volume":"128","author":"Ali","year":"2016","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1016\/j.jacc.2019.10.038","article-title":"Cardiovascular events among adults treated with chimeric antigen receptor T-cells (CAR-T)","volume":"74","author":"Alvi","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1200\/jco.2016.70.5400","article-title":"Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American society of clinical oncology clinical practice guideline","volume":"35","author":"Armenian","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"B5","article-title":"Dobutamine","volume-title":"StatPearls","author":"Ashkar","year":"2025"},{"key":"B6","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s11912-018-0690-1","article-title":"Cardiotoxicity of immunotherapy: incidence, diagnosis, and management","volume":"20","author":"Asnani","year":"2018","journal-title":"Curr. Oncol. Rep."},{"key":"B7","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/s11936-017-0546-2","article-title":"Role of imaging in cardio-oncology","volume":"19","author":"Avelar","year":"2017","journal-title":"Curr. Treat. Opt. Cardiovasc Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2868","DOI":"10.1182\/blood-2019-127566","article-title":"Outpatient treatment with lisocabtagene maraleucel (liso-cel) in three ongoing clinical studies in relapsed\/refractory (R\/R) B cell non-hodgkin lymphoma (NHL), including second-line transplant ineligible patients: transcend NHL 001, outreach, and PILOT","volume":"134","author":"Bachier","year":"2019","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","first-page":"193","DOI":"10.7150\/ijms.3635","article-title":"Cancer and radiation therapy: current advances and future directions","volume":"9","author":"Baskar","year":"2012","journal-title":"Int. J. Med. Sci."},{"key":"B10","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13054-024-04851-0","article-title":"Toxicities, intensive care management, and outcome of chimeric antigen receptor T cells in adults: an update","volume":"28","author":"Bellal","year":"2024","journal-title":"Crit. Care"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e002590","DOI":"10.1136\/openhrt-2023-002590","article-title":"Arrhythmias and cardiac MRI associations in patients with established cardiac dystrophinopathy","volume":"11","author":"Bourke","year":"2024","journal-title":"Open Heart"},{"key":"B12","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","article-title":"Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management","volume":"34","author":"Brudno","year":"2019","journal-title":"Blood Rev."},{"key":"B13","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41571-024-00903-0","article-title":"Current understanding and management of CAR T cell-associated toxicities","volume":"21","author":"Brudno","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1200\/jco.2018.77.8084","article-title":"T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma","volume":"36","author":"Brudno","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1016\/j.bbmt.2018.05.014","article-title":"Cardiac profile of chimeric antigen receptor T cell therapy in children: a single-institution experience","volume":"24","author":"Burstein","year":"2018","journal-title":"Biol. Blood Marrow Transpl."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1090103","DOI":"10.3389\/fcvm.2023.1090103","article-title":"Chimeric antigen receptor-T cell therapy-related cardiotoxicity in adults and children cancer patients: a clinical appraisal","volume":"10","author":"Camilli","year":"","journal-title":"Front. Cardiovasc Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1016\/j.cjca.2022.10.027","article-title":"Incessant pericarditis successfully treated with anakinra in a patient on active treatment for mediastinal lymphoma","volume":"39","author":"Camilli","year":"","journal-title":"Can. J. Cardiol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"3371","DOI":"10.3760\/cma.j.cn112137-20240510-01091","article-title":"Chinese expert consensus on cardiac biomarkers for monitoring and management of cardiovascular toxicity in cancer therapy (2024 edition)","volume":"104","year":"2024","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"B19","doi-asserted-by":"publisher","first-page":"924208","DOI":"10.3389\/fonc.2022.924208","article-title":"Cardiovascular effects associated with chimeric antigen receptor T cell therapy in cancer patients: a meta-analysis","volume":"12","author":"Chen","year":"2022","journal-title":"Front. Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s44348-024-00014-5","article-title":"Cancer therapy-related cardiac dysfunction and the role of cardiovascular imaging: systemic review and opinion paper from the working group on cardio-oncology of the Korean society of cardiology","volume":"32","author":"Cho","year":"2024","journal-title":"J. Cardiovasc. Imaging"},{"key":"B21","doi-asserted-by":"publisher","first-page":"30","DOI":"10.12997\/jla.2025.14.1.30","article-title":"Atherosclerotic cardiovascular disease in cancer survivors: current evidence, risk prediction, prevention, and management","volume":"14","author":"Choi","year":"2025","journal-title":"J. Lipid Atheroscler."},{"key":"B22","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1038\/s41409-019-0602-5","article-title":"Insight into mechanisms associated with cytokine release syndrome and neurotoxicity after CD19 CAR-T cell immunotherapy","volume":"54","author":"Chou","year":"2019","journal-title":"Bone Marrow Transpl."},{"key":"B23","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.clinbiochem.2014.10.013","article-title":"Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity","volume":"48","author":"Christenson","year":"2015","journal-title":"Clin. Biochem."},{"key":"B24","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1097\/ppo.0000000000000515","article-title":"Cytokine release syndrome biology and management","volume":"27","author":"Cobb","year":"2021","journal-title":"Cancer J."},{"key":"B25","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s11864-023-01175-z","article-title":"A comprehensive review of cancer drug-induced cardiotoxicity in blood cancer patients: current perspectives and therapeutic strategies","volume":"25","author":"Costanzo","year":"2024","journal-title":"Curr. Treat. Opt. Oncol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"5181","DOI":"10.3390\/cancers13205181","article-title":"Cellular therapy updates in B-cell lymphoma: the state of the CAR-T","volume":"13","author":"Crees","year":"2021","journal-title":"Cancers"},{"key":"B27","doi-asserted-by":"publisher","first-page":"djv439","DOI":"10.1093\/jnci\/djv439","article-title":"Chimeric antigen receptors modified T-cells for cancer therapy","volume":"108","author":"Dai","year":"2016","journal-title":"J. Natl. Cancer Inst."},{"key":"B28","doi-asserted-by":"publisher","first-page":"15330338221132927","DOI":"10.1177\/15330338221132927","article-title":"Adverse cardiac effects of CAR T-cell therapy: characteristics, surveillance, management, and future research directions","volume":"21","author":"Dalal","year":"2022","journal-title":"Technol. Cancer Res. Treat."},{"key":"B29","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1002\/mc.23354","article-title":"Amateur antigen-presenting cells in the tumor microenvironment","volume":"61","author":"Darragh","year":"2022","journal-title":"Mol. Carcinog."},{"key":"B30","doi-asserted-by":"publisher","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1186\/s12872-020-01665-0","article-title":"Reverse takotsubo cardiomyopathy in fulminant COVID-19 associated with cytokine release syndrome and resolution following therapeutic plasma exchange: a case-report","volume":"20","author":"Faqihi","year":"2020","journal-title":"BMC Cardiovasc Disord."},{"key":"B32","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/nature06185","article-title":"Phagocyte-derived catecholamines enhance acute inflammatory injury","volume":"449","author":"Flierl","year":"2007","journal-title":"Nature"},{"key":"B33","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1002\/phar.2414","article-title":"Advances in CAR T therapy for hematologic malignancies","volume":"40","author":"Freyer","year":"2020","journal-title":"Pharmacotherapy"},{"key":"B34","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.jaccao.2022.07.014","article-title":"Cardiotoxicity of T-cell antineoplastic therapies: JACC: CardioOncology primer","volume":"4","author":"Ganatra","year":"2022","journal-title":"JACC CardioOncol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1161\/circulationaha.120.048100","article-title":"Chimeric antigen receptor T-cell therapy-associated cardiomyopathy in patients with refractory or relapsed non-hodgkin lymphoma","volume":"142","author":"Ganatra","year":"2020","journal-title":"Circulation"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.tmrv.2006.09.001","article-title":"Acetaminophen and diphenhydramine premedication for allergic and febrile nonhemolytic transfusion reactions: good prophylaxis or bad practice?","volume":"21","author":"Geiger","year":"2007","journal-title":"Transfus. Med. Rev."},{"key":"B37","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jaccao.2020.02.011","article-title":"CAR T cell therapy\u2013related cardiovascular outcomes and management: systemic disease or direct cardiotoxicity?","volume":"2","author":"Ghosh","year":"2020","journal-title":"JACC CardioOncology"},{"key":"B38","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat. Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"e230622206353","DOI":"10.2174\/1573403x18666220623152350","article-title":"Cardiovascular toxicities with chimeric antigen receptor T-cell therapy","volume":"19","author":"Gill","year":"2023","journal-title":"Curr. Cardiol. Rev."},{"key":"B40","doi-asserted-by":"publisher","first-page":"2378543","DOI":"10.1080\/21645515.2024.2378543","article-title":"Approved CAR-T therapies have reproducible efficacy and safety in clinical practice","volume":"20","author":"Goyco Vera","year":"2024","journal-title":"Hum. Vaccin Immunother."},{"key":"B41","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1042\/cs20060024","article-title":"Therapeutic potential of immunostimulatory monoclonal antibodies","volume":"111","author":"Gray","year":"2006","journal-title":"Clin. Sci."},{"key":"B42","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.tmrv.2019.01.005","article-title":"Risks and benefits of chimeric antigen receptor T-cell (CAR-T) therapy in cancer: a systematic review and meta-analysis","volume":"33","author":"Grigor","year":"2019","journal-title":"Transfus. Med. Rev."},{"key":"B43","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1001\/jama.2013.1363","article-title":"Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy","volume":"309","author":"Gulati","year":"2013","journal-title":"JAMA"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1158\/2159-8290.Cd-17-0698","article-title":"Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov."},{"key":"B45","doi-asserted-by":"publisher","first-page":"4764","DOI":"10.3390\/molecules25204764","article-title":"Antibody-drug conjugates for cancer therapy","volume":"25","author":"Hafeez","year":"2020","journal-title":"Molecules"},{"key":"B46","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40164-020-00171-5","article-title":"Macrophage, the potential key mediator in CAR-T related CRS","volume":"9","author":"Hao","year":"2020","journal-title":"Exp. Hematol. Oncol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.3390\/ijms23031833","article-title":"Granzymes: the molecular executors of immune-mediated cytotoxicity","volume":"23","author":"Hay","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B49","doi-asserted-by":"publisher","first-page":"39","DOI":"10.4137\/bic.S31798","article-title":"The role of biomarkers in decreasing risk of cardiac toxicity after cancer therapy","volume":"8","author":"Henri","year":"2016","journal-title":"Biomark. Cancer"},{"key":"B50","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.reuma.2011.08.002","article-title":"Abatacept mechanism of action: concordance with its clinical profile","volume":"8","author":"Herrero-Beaumont","year":"2012","journal-title":"Reumatol. Clin."},{"key":"B51","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13045-024-01639-1","article-title":"Advances in CAR-T cell therapy for hematologic and solid malignancies: latest updates from 2024 ESMO Congress","volume":"17","author":"Huang","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"6299","DOI":"10.1158\/1078-0432.Ccr-20-1739","article-title":"Itacitinib (INCB039110), a JAK1 inhibitor, reduces cytokines associated with cytokine release syndrome induced by CAR T-cell therapy","volume":"26","author":"Huarte","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"B53","doi-asserted-by":"publisher","first-page":"650295","DOI":"10.3389\/fphar.2021.650295","article-title":"Ruxolitinib, a JAK1\/2 inhibitor, ameliorates cytokine storm in experimental models of hyperinflammation syndrome","volume":"12","author":"Huarte","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00281-024-01013-w","article-title":"Riding the storm: managing cytokine-related toxicities in CAR-T cell therapy","volume":"46","author":"Hughes","year":"2024","journal-title":"Seminars Immunopathol."},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03478-6","article-title":"Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies","author":"Jadlowsky","year":"2025","journal-title":"Nat. Medicine"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1002\/jmri.26895","article-title":"MRI in cardio-oncology: a review of cardiac complications in oncologic care","volume":"50","author":"Jeong","year":"2019","journal-title":"J. Magn. Reson Imaging"},{"key":"B57","doi-asserted-by":"publisher","first-page":"790612","DOI":"10.3389\/fcvm.2021.790612","article-title":"IL-6\/STAT3 signaling promotes cardiac dysfunction by upregulating FUNDC1-dependent mitochondria-associated endoplasmic reticulum membranes formation in sepsis mice","volume":"8","author":"Jiang","year":"2021","journal-title":"Front. Cardiovasc Med."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/j.neuroscience.2005.06.090","article-title":"Catecholamines mediate stress-induced increases in peripheral and central inflammatory cytokines","volume":"135","author":"Johnson","year":"2005","journal-title":"Neuroscience"},{"key":"B59","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s11912-024-01634-2","article-title":"Cardiotoxic effects following CAR-T cell therapy: a literature review","volume":"27","author":"Joseph","year":"2025","journal-title":"Curr. Oncol. Rep."},{"key":"B60","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B61","doi-asserted-by":"publisher","first-page":"382","DOI":"10.3390\/biom13020382","article-title":"Early use of corticosteroids following CAR T-cell therapy correlates with reduced risk of high-grade CRS without negative impact on neurotoxicity or treatment outcome","volume":"13","author":"Lakomy","year":"2023","journal-title":"Biomolecules"},{"key":"B62","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1634\/theoncologist.2018-0028","article-title":"FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome","volume":"23","author":"Le","year":"2018","journal-title":"Oncologist"},{"key":"B63","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"B64","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/s0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"B65","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol. Blood Marrow Transpl."},{"key":"B66","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.jaccao.2020.04.012","article-title":"Cardiovascular effects of CAR T cell therapy: a retrospective study","volume":"2","author":"Lefebvre","year":"2020","journal-title":"JACC CardioOncol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1038\/s43018-024-00785-2","article-title":"Multidimensional analysis reveals predictive markers for CAR-T efficacy","volume":"5","author":"Letscher","year":"2024","journal-title":"Nat. Cancer"},{"key":"B68","doi-asserted-by":"publisher","first-page":"3042","DOI":"10.26355\/eurrev_201904_17586","article-title":"Effect of IL-6-mediated STAT3 signaling pathway on myocardial apoptosis in mice with dilated cardiomyopathy","volume":"23","author":"Li","year":"","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"B69","doi-asserted-by":"publisher","first-page":"eaax0428","DOI":"10.1126\/scitranslmed.aax0428","article-title":"Targeting cellular heterogeneity with CXCR2 blockade for the treatment of therapy-resistant prostate cancer","volume":"11","author":"Li","year":"","journal-title":"Sci. Transl. Med."},{"key":"B70","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1182\/blood-2013-03-490565","article-title":"Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma","volume":"122","author":"Linette","year":"2013","journal-title":"Blood"},{"key":"B71","doi-asserted-by":"publisher","first-page":"873","DOI":"10.3390\/diagnostics15070873","article-title":"Neuroinflammatory mechanisms of adult sepsis-associated encephalopathy: implications for blood\u2013brain barrier disruption and oxidative stress","volume":"15","author":"Liu","year":"2025","journal-title":"Diagnostics"},{"key":"B72","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European hematology association (EHA), the European society for therapeutic radiology and oncology (ESTRO) and the international cardio-oncology society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur. Heart J."},{"key":"B73","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/nbt0102-70","article-title":"Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta\/CD28 receptor","volume":"20","author":"Maher","year":"2002","journal-title":"Nat. Biotechnol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1093\/eurheartj\/ehad117","article-title":"Biomarkers and cardiovascular outcomes in chimeric antigen receptor T-cell therapy recipients","volume":"44","author":"Mahmood","year":"2023","journal-title":"Eur. Heart J."},{"key":"B75","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/s41577-018-0042-2","article-title":"CAR T cells for infection, autoimmunity and allotransplantation","volume":"18","author":"Maldini","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"B77","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.freeradbiomed.2023.06.005","article-title":"IL-6\/gp130\/STAT3 signaling contributed to the activation of the PERK arm of the unfolded protein response in response to chronic \u03b2-adrenergic stimulation","volume":"205","author":"Men","year":"2023","journal-title":"Free Radic. Biol. Med."},{"key":"B78","doi-asserted-by":"publisher","first-page":"eaau5907","DOI":"10.1126\/scitranslmed.aau5907","article-title":"The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on\/off switch for CAR T cells","volume":"11","author":"Mestermann","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"B79","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.3892\/or.2019.7335","article-title":"CAR T cell therapy: a new era for cancer treatment (Review)","volume":"42","author":"Mohanty","year":"2019","journal-title":"Oncol. Rep."},{"key":"B80","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1038\/nri2448","article-title":"Exploring the full spectrum of macrophage activation","volume":"8","author":"Mosser","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-024-01100-5","article-title":"Novel strategies to manage CAR-T cell toxicity","author":"Mulvey","year":"2025","journal-title":"Nat. Rev. Drug Discovery"},{"key":"B82","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/hon.2595","article-title":"Managing the toxicities of CAR T-cell therapy","volume":"37","author":"Neelapu","year":"2019","journal-title":"Hematol. Oncol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat. Med."},{"key":"B85","doi-asserted-by":"publisher","first-page":"103693","DOI":"10.1016\/j.htct.2024.06.008","article-title":"From the mechanism of action to clinical management: a review of cardiovascular toxicity in adult treated with CAR-T therapy","volume":"47","author":"Nunes","year":"2024","journal-title":"Hematol. Transfus. Cell Ther."},{"key":"B86","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1111\/trf.14502","article-title":"Cellular collection by apheresis","volume":"58","author":"Padmanabhan","year":"2018","journal-title":"Transfusion"},{"key":"B87","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1111\/bjh.13373","article-title":"JAK1\/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms","volume":"169","author":"Parampalli Yajnanarayana","year":"2015","journal-title":"Br. J. Haematol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"268","DOI":"10.3390\/v13020268","article-title":"Lentiviral vector bioprocessing","volume":"13","author":"Perry","year":"2021","journal-title":"Viruses-Basel"},{"key":"B89","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1158\/2159-8290.Cd-12-0548","article-title":"The basic principles of chimeric antigen receptor design","volume":"3","author":"Sadelain","year":"2013","journal-title":"Cancer Discov."},{"key":"B90","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1200\/edbk_238691","article-title":"The other side of CAR T-cell therapy: cytokine release syndrome, neurologic toxicity, and financial burden","volume":"39","author":"Santomasso","year":"2019","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"B91","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1007\/s00109-005-0014-4","article-title":"Autophagy in innate and adaptive immunity against intracellular pathogens","volume":"84","author":"Schmid","year":"2006","journal-title":"J. Mol. Medicine-Jmm"},{"key":"B92","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1038\/ni.3321","article-title":"Transcription factor Nr4a1 couples sympathetic and inflammatory cues in CNS-recruited macrophages to limit neuroinflammation","volume":"16","author":"Shaked","year":"2015","journal-title":"Nat. Immunol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"e001159","DOI":"10.1136\/jitc-2020-001159","article-title":"Impact of cytokine release syndrome on cardiac function following CD19 CAR-T cell therapy in children and young adults with hematological malignancies","volume":"8","author":"Shalabi","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"B94","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1002\/phar.1900","article-title":"Chimeric antigen receptor T cells in hematologic malignancies","volume":"37","author":"Shank","year":"2017","journal-title":"Pharmacotherapy"},{"key":"B95","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"B96","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"B97","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40959-024-00284-4","article-title":"SGLT2 inhibitors for prevention and management of cancer treatment-related cardiovascular toxicity: a review of potential mechanisms and clinical insights","volume":"11","author":"Simela","year":"2025","journal-title":"Cardio-Oncology"},{"key":"B98","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s11897-015-0258-4","article-title":"Utilizing cardiac biomarkers to detect and prevent chemotherapy-induced cardiomyopathy","volume":"12","author":"Singh","year":"2015","journal-title":"Curr. Heart Fail Rep."},{"key":"B99","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s11897-020-00453-3","article-title":"Personalized approach to cancer treatment-related cardiomyopathy","volume":"17","author":"Slivnick","year":"2020","journal-title":"Curr. Heart Fail Rep."},{"key":"B100","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1182\/blood-2018-10-881722","article-title":"GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts","volume":"133","author":"Sterner","year":"2019","journal-title":"Blood"},{"key":"B101","unstructured":"Kymriah"},{"key":"B102","unstructured":"Yescarta"},{"key":"B103","unstructured":"Tecartus\n          \n          \n          2020"},{"key":"B104","unstructured":"Breyanzi\n          \n          \n          2021"},{"key":"B105","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/s1286-4579(00)00329-4","article-title":"The role of interleukin 15 in mounting an immune response against microbial infections","volume":"2","author":"Yoshikai","year":"2000","journal-title":"Microbes Infect."},{"key":"B106","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13045-018-0681-6","article-title":"A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma","volume":"11","author":"Zhao","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"B107","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1186\/s12967-024-05705-7","article-title":"Efficacy and safety of CAR-T therapy targeting CLL1 in patients with extramedullary diseases of acute myeloid leukemia","volume":"22","author":"Zhao","year":"2024","journal-title":"J. Transl. Med."},{"key":"B108","doi-asserted-by":"publisher","first-page":"464","DOI":"10.3389\/fphar.2017.00464","article-title":"Attenuation of TNF-\u03b1-Induced inflammatory injury in endothelial cells by ginsenoside Rb1 via inhibiting NF-\u03baB, JNK and p38 signaling pathways","volume":"8","author":"Zhou","year":"2017","journal-title":"Front. Pharmacol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1578157\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:13:30Z","timestamp":1746663210000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1578157\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,8]]},"references-count":108,"alternative-id":["10.3389\/fphar.2025.1578157"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1578157","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,8]]},"article-number":"1578157"}}